CareDx’s Quiet Period Will Expire on August 26th (NASDAQ:CDNA)
CareDx’s (NASDAQ:CDNA) quiet period is set to expire on Tuesday, August 26th. CareDx had issued 4,000,000 shares in its public offering on July 17th, AmericanBankingNews.com reports. The total size of the offering was $40,000,000 based on an initial share price of $10.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Several analysts have recently commented on the stock. Analysts at Piper Jaffray initiated coverage on shares of CareDx in a research note on Monday, August 11th. They set an “overweight” rating and a $13.00 price target on the stock. Separately, analysts at Raymond James initiated coverage on shares of CareDx in a research note on Monday, August 11th. They set an “outperform” rating and a $12.50 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of CareDx in a research note on Monday, August 11th. They set an “outperform” rating and a $13.00 price target on the stock.
Shares of CareDx (NASDAQ:CDNA) traded down 1.37% during mid-day trading on Thursday, hitting $10.05. The stock had a trading volume of 1,510 shares. CareDx has a 52-week low of $8.49 and a 52-week high of $10.88. The stock’s 50-day moving average is $9.8 and its 200-day moving average is $9.8. The company’s market cap is $116.3 million.
CareDx, Inc is a commercial stage company that develops markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a patient’s lifetime.
Receive News & Ratings for CareDx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.